Gossamer Bio Regains Full Rights to Seralutinib with Clarity on Regulatory Path and Strengthened Balance Sheet
Market Chameleon (Tue, 28-Jul 10:32 AM)
Gossamer Bio Locks in Global Rights and Regulatory Path for Seralutinib—Strengthened Balance Sheet Provides Flexibility
Market Chameleon (Mon, 27-Jul 10:30 AM)
